Novel RAS Inhibitor, MCI-062, potently and selectively inhibits the growth of KRAS mutant pancreatic tumor cells by blocking GTP loading of RAS. Mattox et al. AACR Annual Meeting 2019. [Download Poster]
Targeting RAS and downstream signaling in high-grade serious ovarian carcinoma with novel RAS inhibitors. Mattox et al. AACR Annual Meeting 2019. [Download Poster]
A novel RAS Inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity. Keeton et al. AACR Annual Meeting 2019.
PDE10 inhibition is associated with reduced colon tumor formation: discovery of a novel PDE10 inhibitor, MCI-030. Ward et al. AACR Annual Meeting 2019. [Download Poster]
A novel PDE10/beta-catenin inhibitor, MCI-048, suppresses lung tumorigenesis to block metastasis. Zhu et al. AACR Annual Meeting 2019.
Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling. Oncotarget. 2017 Aug 27;8(41):69264-69280.
β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. Oncotarget. 2016 Feb 2;7(5):5353-65.
Phosphodiesterase 10A: a novel target for selective inhibition of colon tumor cell growth and β-catenin-dependent TCF transcriptional activity. 2015 Mar 19;34(12):1499-509.
Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. 2015 Sep 29;6(29):27403-15.
View Online Download PDF
Address: One Kendall Square, Building 1400E, Suite 14-105, Cambridge, MA 02139 (map)
Investor relations: Ashley Robinson, LifeSci Advisors Email: firstname.lastname@example.org
[advanced_iframe src=”https://www.nasdaq.com/symbol/ancn” width=”100%” height=”600″]
Mr. Burgin has served as BioCanCell’s CFO and COO since October 2016, having previously served as CEO from 2012 to 2016, and as CFO from 2011 to 2012. From 2006 to 2011, he was CFO of Radcom, Ltd. (NASDAQ: RDCM), a service assurance provider, and CFO of XTL Biopharmaceuticals (TASE: XTL, NASDAQ: XTLB), a drug development company, from 1999 to 2006, where he took an active role in the process of listing its shares on the NASDAQ, London Stock Exchange and TASE, and in raising $113 million in four financing rounds. Between 1997 and 1999, he was CFO of YLR Capital Markets, a publicly-traded Israeli investment bank, and rose to become a Senior Manager at Kesselman & Kesselman, the Israeli member of PricewaterhouseCoopers International, Ltd, between 1984 and 1997. Mr. Burgin earned an M.B.A. and a B.A. in Accounting and Economics from Tel-Aviv University and is certified in Israel as a CPA.
Dr. Gilon has served as BioCanCell’s VP of R&D since January 2013 and brings more than 15 years of research experience and a vast network of collaborative relationships from academic and clinical settings. As part of her overall role, Dr. Gilon represents the company’s science in FDA meetings and global regulatory and advisory boards. Dr. Gilon also leads BioCanCell’s pre-clinical activities to enable the successful initiation of the company’s clinical programs.
Dr. Gilon earned her PhD in the field of developmental biology from the Hebrew University of Jerusalem and completed her post-doctoral studies under the mentorship of Prof. Avraham Hochberg, BioCanCell’s Co-Founder and former Chief Scientist.
Dr. Moore has more than 16 years of experience in the pharmaceutical industry, and has participated in four registration programs and five global drug launches.
Prior to joining BioCanCell, Dr. Moore served as the vice president of medical affairs at ARIAD Pharmaceuticals, where he was responsible for global medical affairs strategy, planning and execution. Prior to joining ARIAD, Dr. Moore served as a lead drug developer in three different global pharmaceutical companies (Sanofi, GSK, BMS) and held positions of growing responsibility (director to AVP). In addition, Dr. Moore served as the global head of medical affairs at GPC Biotech and as the global medical director of GU oncology at Oncura (a business unit of GE Healthcare).
Dr. Moore earned Bachelor of Science and MD degrees from the Sackler School of Medicine (Tel Aviv University, Israel), followed by training in internal medicine at the E. Wolfson Medical Center and in Ob/Gyn at the Meir Medical Center. In 2006, he received an MBA from the LeBow College of Business at Drexel University in Philadelphia.
Dr. Knickerbocker is Senior Vice President, Clinical Development at BioCanCell since March 2018. Prior to this Dr. Knickerbocker led the Biomedical Data Sciences and Information group at ARIAD Pharmaceuticals from 2012 until its acquisition by Takeda in 2017. At ARIAD, he led statistics and data management functions through multiple successful oncology submissions. Prior to this, Dr. Knickerbocker served as a Vice President at Genzyme corporation from 2004 to 2012, where his positions included leading the biostatistics, data management, and medical writing functions for the transplant/oncology business and global head of biostatistics and statistical programming. From 1999 to 2004 Dr. Knickerbocker was the statistical site head for Pfizer Inc. in Ann Arbor, MI. From 1993 to 1999, he held positions at Eli Lilly and Company, leading projects in women’s health and oncology. He has a B.S. degree in Applied Mathematics and his M.S. and Ph.D. degrees in Statistics from Texas A&M University.
Mr. Daly has served as BioCanCell’s Vice President of Clinical Operations since March 2018 and brings more than a decade of experience and an ample network of synergetic relationships to his role. Mr. Daly joined BioCanCell from ARIAD Pharmaceuticals, where he most recently served as the Vice President of Clinical Operations. Sean led the clinical operations group at ARIAD for five years, building upon various operational roles held at ARIAD since 2004. In addition to his experience at ARIAD, he has held positions with Wyeth Research (formerly Genetics Institute) and Agouron Pharmaceuticals. Sean is a graduate of the University of California at San Diego where he received his B.S. in Biochemistry and Cell Biology.
-ARIAD Pharmaceuticals: CMO, SVP of Clinical R&D
-Led development and approvals of two oncology drugs
-Harvard College: BA: U. Penn: MD, PhD; MIT: post-doctoral fellowship
-MGH residency, DFCI fellowship, Harvard Medical School faculty
-MGH: Physician and founder of the melanoma research programs
-Dana-Farber/Harvard Cancer Center: skin cancer program leader